Executive Summary: A Breach of Public Trust
In a significant crackdown on healthcare exploitation, the owner and operator of an Oregon-based diagnostic testing enterprise has admitted to orchestrating a sophisticated, multi-year scheme to defraud federal health programs and private insurance carriers. Mehrdad Gerami, 67, the proprietor of Coastal Diagnostic Testing Group, entered a formal plea of guilty to conspiracy to commit healthcare fraud, bringing an end to a fraudulent operation that resulted in an estimated financial loss of more than $2.1 million.
The case, which centers on the systematic falsification of billing records for sleep diagnostic services, highlights the vulnerabilities within the healthcare reimbursement system and the aggressive efforts of federal oversight agencies to root out such misconduct. Gerami’s admission of guilt marks a turning point in an investigation that spans several years and multiple communities across the Oregon coastline.
Chronology of the Fraud: From Clinical Service to Criminal Enterprise
The timeline of the fraudulent activity, as established by federal investigators and court documents, spans from 2021 through the present. During this period, Coastal Diagnostic Testing Group—which maintained a network of facilities in Coos Bay, Brookings, Reedsport, Florence, and Roseburg—functioned not merely as a diagnostic provider, but as a mechanism for systemic billing abuse.
The Mechanism of Deception
According to the plea agreement and federal prosecutors, the scheme relied on two distinct but equally damaging methods of financial deception:
- Upcoding and Billing Misrepresentation: The company routinely performed inexpensive, at-home sleep apnea testing. However, when submitting claims to the U.S. Department of Health and Human Services (HHS), the Veterans Health Administration (VHA), and private insurers, Gerami directed his staff to bill for intensive, in-office diagnostic sleep studies. Because in-office studies command significantly higher reimbursement rates than home-based alternatives, this "upcoding" allowed the company to siphon excessive funds from both taxpayer-funded and private insurance pools.
- Ghost Procedures: Perhaps the most egregious aspect of the fraud involved the fabrication of services entirely. During months when productivity at specific office locations waned, Gerami reportedly instructed his employees to identify patient information in the company’s database and submit billing claims for sleep studies that never actually occurred. These "ghost" services were generated solely to meet internal revenue targets, regardless of the patient’s clinical needs or the reality of the diagnostic schedule.
Investigation and Prosecution
The trail of illicit activity eventually drew the attention of the Health and Human Services Office of Inspector General (HHS-OIG) and the Department of Veterans Affairs Office of Inspector General (VA-OIG). These agencies, tasked with protecting the integrity of federal healthcare programs, utilized data analytics to identify irregularities in the billing patterns emanating from Coastal Diagnostic Testing Group.
Gerami was officially charged by information on June 22, 2026. The investigation, spearheaded by Assistant U.S. Attorneys Joseph Huynh and Julia Jarrett, meticulously traced the fraudulent claims back to Gerami’s direct oversight. By admitting to his role, Gerami has acknowledged that he did not merely permit this activity, but actively conspired with and directed his subordinates to execute the fraudulent billing cycles.
Supporting Data and Financial Impact
The total financial damage caused by the scheme is estimated at $2,124,363.41. This figure represents a combination of overpayments for legitimately performed home tests and total payments for fraudulent, non-existent tests.
Breakdown of the Loss
- Federal Impact: A significant portion of the $2.1 million loss was shouldered by federal taxpayers through HHS and the VA. The exploitation of the Veterans Health Administration is particularly noted, as it diverted resources intended for the care of those who served in the military.
- Private Sector Exposure: Numerous private insurance companies were also targeted. The impact of such fraud on private insurers is often passed down to consumers in the form of higher premiums and increased out-of-pocket costs, illustrating that the victim pool extends far beyond the government agencies initially billed.
- Operational Scope: The breadth of the fraud was enabled by the geographic reach of Coastal Diagnostic Testing Group. By maintaining offices across five Oregon municipalities, Gerami was able to distribute the fraudulent billing across multiple billing profiles, a tactic designed to avoid triggering automated fraud detection algorithms.
Official Responses and Legal Consequences
The resolution of this case underscores the high stakes involved in federal healthcare fraud prosecutions. Gerami now faces the severe consequences of his actions as he awaits sentencing.
The Sentencing Outlook
Under the terms of the plea agreement, Gerami faces a potential maximum sentence of 10 years in federal prison. In addition to the risk of incarceration, he faces a criminal fine of up to $250,000 and three years of supervised release following any term of imprisonment.
Central to the plea agreement is the requirement of restitution. Gerami has committed to paying the full amount of the $2.1 million loss back to the defrauded entities. This restitution is intended to make the victimized agencies whole, though the long-term administrative costs of the investigation and the impact on patient trust are harder to quantify.
A U.S. District Court judge is scheduled to deliver the final sentence on January 26, 2027. The severity of the sentence will likely serve as a barometer for how the judiciary views the exploitation of public health programs in the current regulatory climate.
Implications for the Healthcare Industry
The Coastal Diagnostic Testing Group case serves as a cautionary tale for the medical community and provides several critical takeaways for the future of healthcare oversight.
Increased Scrutiny on Diagnostic Billing
Sleep studies have become an increasingly popular diagnostic tool as awareness of sleep disorders, such as obstructive sleep apnea, has grown. With the rise of telehealth and home-based monitoring, the gap in reimbursement rates between home tests and in-office studies has become a focal point for both providers and auditors. Regulators are now expected to increase their scrutiny of providers who show anomalous ratios of in-office versus home testing, particularly those with multiple locations.
The Responsibility of Leadership
The prosecution of Gerami emphasizes that the "tone at the top" is a critical factor in institutional compliance. By directing his employees to engage in fraudulent billing, Gerami transformed a clinical practice into a criminal enterprise. This case serves as a reminder that healthcare providers, regardless of their size or location, are subject to rigorous federal standards. For employees in such environments, the case highlights the importance of whistleblowing channels, as the fraud in this case was dismantled through the investigative power of federal oversight, likely aided by internal data and reporting.
Protecting Patient Trust
Perhaps the most damaging aspect of this case is the degradation of patient trust. Patients in Coos Bay, Brookings, and surrounding areas visited these clinics believing they were receiving professional medical guidance for often debilitating sleep conditions. The realization that their personal health information was being used as a tool for financial theft is a betrayal of the physician-patient relationship.
As the legal proceedings conclude, the healthcare industry in Oregon and beyond will be watching closely. The outcome of the sentencing on January 26, 2027, will be a final statement on the intolerance of the American justice system toward those who compromise the integrity of healthcare for personal gain. For the victims—both the institutions that lost millions and the patients whose medical care was treated as a commodity—the conclusion of this case offers a measure of justice, even as the industry works to implement better safeguards against future abuse.
